Cardiovascular Risk in Patients with Subclinical Hypothyroidism

Leonidas H. Duntas, Luca Chiovato

Research output: Contribution to journalArticle

Abstract

Subclinical hypothyroidism (SCH) has been associated with increased cardiovascular mortality due to adverse effects mainly on lipids and blood pressure (BP). There is evidence that SCH, especially in patients with thyroid-stimulating hormone (TSH) >10mU/l, may increase cardiovascular risk. Some uncertainty exists regarding the association of SCH with BP; however, that the coexistence of SCH with BP and hypercholesterolaemia has a negative cardiovascular impact is beyond doubt. Insulin resistance, by modulating various risk factors including coagulation, may potentially increase cardiovascular risk. Periodic health examinations including screening has been advised in patients >35 years of age, while treatment with thyroxine should be tailored to each patient.

Original languageEnglish
Pages (from-to)157-160
Number of pages4
JournalUS Endocrinology
Volume10
Issue number2
DOIs
Publication statusPublished - 2014

Fingerprint

Hypothyroidism
Blood Pressure
Thyrotropin
Hypercholesterolemia
Thyroxine
Uncertainty
Insulin Resistance
Lipids
Mortality
Health
Therapeutics

Keywords

  • blood pressure
  • cardiovascular risk
  • lipids
  • Subclinical hypothyroidism
  • the metabolic syndrome
  • thyroid-stimulating hormone

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Cardiovascular Risk in Patients with Subclinical Hypothyroidism. / Duntas, Leonidas H.; Chiovato, Luca.

In: US Endocrinology, Vol. 10, No. 2, 2014, p. 157-160.

Research output: Contribution to journalArticle

Duntas, Leonidas H. ; Chiovato, Luca. / Cardiovascular Risk in Patients with Subclinical Hypothyroidism. In: US Endocrinology. 2014 ; Vol. 10, No. 2. pp. 157-160.
@article{a92edd32542d4225ae38474ba3f4beee,
title = "Cardiovascular Risk in Patients with Subclinical Hypothyroidism",
abstract = "Subclinical hypothyroidism (SCH) has been associated with increased cardiovascular mortality due to adverse effects mainly on lipids and blood pressure (BP). There is evidence that SCH, especially in patients with thyroid-stimulating hormone (TSH) >10mU/l, may increase cardiovascular risk. Some uncertainty exists regarding the association of SCH with BP; however, that the coexistence of SCH with BP and hypercholesterolaemia has a negative cardiovascular impact is beyond doubt. Insulin resistance, by modulating various risk factors including coagulation, may potentially increase cardiovascular risk. Periodic health examinations including screening has been advised in patients >35 years of age, while treatment with thyroxine should be tailored to each patient.",
keywords = "blood pressure, cardiovascular risk, lipids, Subclinical hypothyroidism, the metabolic syndrome, thyroid-stimulating hormone",
author = "Duntas, {Leonidas H.} and Luca Chiovato",
year = "2014",
doi = "10.17925/USE.2014.10.02.157",
language = "English",
volume = "10",
pages = "157--160",
journal = "US Endocrinology",
issn = "1758-3918",
publisher = "Touch Briefings",
number = "2",

}

TY - JOUR

T1 - Cardiovascular Risk in Patients with Subclinical Hypothyroidism

AU - Duntas, Leonidas H.

AU - Chiovato, Luca

PY - 2014

Y1 - 2014

N2 - Subclinical hypothyroidism (SCH) has been associated with increased cardiovascular mortality due to adverse effects mainly on lipids and blood pressure (BP). There is evidence that SCH, especially in patients with thyroid-stimulating hormone (TSH) >10mU/l, may increase cardiovascular risk. Some uncertainty exists regarding the association of SCH with BP; however, that the coexistence of SCH with BP and hypercholesterolaemia has a negative cardiovascular impact is beyond doubt. Insulin resistance, by modulating various risk factors including coagulation, may potentially increase cardiovascular risk. Periodic health examinations including screening has been advised in patients >35 years of age, while treatment with thyroxine should be tailored to each patient.

AB - Subclinical hypothyroidism (SCH) has been associated with increased cardiovascular mortality due to adverse effects mainly on lipids and blood pressure (BP). There is evidence that SCH, especially in patients with thyroid-stimulating hormone (TSH) >10mU/l, may increase cardiovascular risk. Some uncertainty exists regarding the association of SCH with BP; however, that the coexistence of SCH with BP and hypercholesterolaemia has a negative cardiovascular impact is beyond doubt. Insulin resistance, by modulating various risk factors including coagulation, may potentially increase cardiovascular risk. Periodic health examinations including screening has been advised in patients >35 years of age, while treatment with thyroxine should be tailored to each patient.

KW - blood pressure

KW - cardiovascular risk

KW - lipids

KW - Subclinical hypothyroidism

KW - the metabolic syndrome

KW - thyroid-stimulating hormone

UR - http://www.scopus.com/inward/record.url?scp=84988369319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988369319&partnerID=8YFLogxK

U2 - 10.17925/USE.2014.10.02.157

DO - 10.17925/USE.2014.10.02.157

M3 - Article

AN - SCOPUS:84988369319

VL - 10

SP - 157

EP - 160

JO - US Endocrinology

JF - US Endocrinology

SN - 1758-3918

IS - 2

ER -